Frequency of symptomatic hypotension in hospitalized patients with HFrEF treated with NRA: retrospective analysis in a university hospital
DOI:
https://doi.org/10.61182/rnavmed.v11n1a2Keywords:
Heart Failure, Reduced Ejection Fraction, Angiotensin Receptor Antagonists, Hypotension, Neprilysin InhibitorsAbstract
Introduction: Heart failure with reduced ejection fraction (HFrEF) is one of the leading causes of cardiovascular morbidity and mortality. Treatment with angiotensin receptor-neprilysin inhibitors (ARNIs) has shown benefits in reducing clinical events; however, their use may be associated with adverse effects.
Methods: Observational, retrospective, and analytical study conducted at a hospital in Bogotá between January 2023 and January 2024. The study included 100 adult patients with HFrEF (left ventricular ejection fraction <45%) treated with ARNIs, excluding those with a history of hypotension or contraindications to their use.
Results: The median age was 68 years, with a male predominance (74%). Orthostatic hypotension occurred in 25% of patients, a frequency higher than that reported in previous clinical studies. Variables significantly associated with adverse effects included baseline potassium levels (p = 0.041), duration of treatment (p = 0.005), and length of hospital stay (p < 0.001). Associations were also observed with decreased glomerular filtration rate, arterial hypertension, and adjustments in the therapeutic regimen.
Conclusions: The frequency of symptomatic hypotension was higher than that reported in pivotal studies, especially among patients with comorbidities. These findings highlight the importance of individualizing dosing and closely monitoring vulnerable populations.
References
1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272–87. https://doi.org/10.1093/cvr/cvac013
2. Lam CSP, Docherty KF, Ho JE, McMurray JJ V., Myhre PL, Omland T. Recent successes in heart failure treatment. Nat Med 2023;29:2424–37. https://doi.org/10.1038/s41591-023-02567-2
3. Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ 696 (Valsartan/Sacubitril) – A Possible New Treatment for Hypertension and Heart Failure. Basic Clin Pharmacol Toxicol 2016;118:14–22. https://doi.org/10.1111/bcpt.12453
4. Iacoviello M, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, et al. Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF. ESC Hear Fail 2024;11:456–65. https://doi.org/10.1002/ehf2.14600
5. Gómez-Mesa JE, Saldarriaga CI, Echeverría LE, Luna P. Colombian heart failure registry (RECOLFACA): methodology and preliminary data. Rev Colomb Cardiol 2021;28:217–30. https://doi.org/10.24875/RCCAR.M21000021
6. Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani MP, et al. Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis. ESC Hear Fail 2021;8:3547–56. https://doi.org/10.1002/ehf2.13547
7. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure. J Am Coll Cardiol 2020;75:1178–95. https://doi.org/10.1016/j.jacc.2019.12.059
8. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
9. Li Z, Qiu ZEPING, Jin WEI. Masked hypotension in patients with heart failure. Eur Heart J 2024;45. https://doi.org/10.1093/eurheartj/ehae666.890
10. Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study. J Cardiol 2024. https://doi.org/10.1016/j.jjcc.2024.09.002
11. Foà A, Vaduganathan M, Claggett BL, Pabon MA, Lu H, Pfeffer MA, et al. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol 2024;83:1731–9. https://doi.org/10.1016/j.jacc.2024.02.035
12. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol 2023;82:1–12. https://doi.org/10.1016/j.jacc.2023.04.019
13. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019;381:1609–20. https://doi.org/10.1056/NEJMoa1908655
14. Cautela J, Tartiere J, Cohen-Solal A, Bellemain‐Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail 2020;22:1357–65. https://doi.org/10.1002/ejhf.1835
15. Patel PA, Heizer G, O’Connor CM, Schulte PJ, Dickstein K, Ezekowitz JA, et al. Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circ Hear Fail 2014;7:918–25. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000872
16. Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). Pharmacoeconomics 2020;38:1219–36. https://doi.org/10.1007/s40273-020-00952-0
17. Kim H-J, Jo S-H. Effect of low blood pressure on prognosis of acute heart failure. Sci Rep 2024;14:15605. https://doi.org/10.1038/s41598-024-66219-2
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Carlos Darío Agudelo-Castañeda, Luis Carlos Chávez-Borja, Carlos Hernán Calderón-Franco
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
